EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Top advances of the year: Cervical cancer

Linda R Duska iD, Sarah E Podwika iD, Leslie M Randall

Cancer · 2024-08 · 130 (15) · 2571-2576

DOI: 10.1002/cncr.35334 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 23.04.2024. Verfasst von Linda R Duska und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Virginia School of Medicine, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Immunotherapy. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The year 2023 was an extraordinary year for the further development and expansion of novel treatments for all patients with cervical cancer, ranging from early stage to later stage and metastatic or recurrent disease. Individuals with early‐stage disease will benefit from less invasive surgery with subsequent improvement in quality of life. The effectiveness of immunotherapy has been demonstrated in upfront, locally advanced cervical cancer and confirmed in advanced metastatic disease. Induction chemotherapy will play a role in some patients with locally advanced disease, particularly those in low resource areas of the world. Novel therapeutics including antibody–drug conjugates have shown efficacy even in pretreated patients. As we continue to explore innovative therapeutics in this space, however, we must also continue to improve the diversity of clinical trial accrual to allow for generalizable results. At the same time, we must focus on eradicating this disease with appropriate screening and vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsImmunotherapyHumansFemaleQuality of LifeNeoplasm StagingInduction Chemotherapy

Stichwörter der Autor:innen

antibody‐drug conjugatescervical cancerchemoradiationchemotherapydiversityearly stageimmunotherapylocally advancedsurgery

Autor:innen und Institutionen

  • University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Massey Comprehensive Cancer Center, VCUHealth, Richmond, Virginia, USA.

ORCID-Profile: Linda R Duska, Sarah E Podwika

Zitieren

APA

Duska, L. R., Podwika, S. E., & Randall, L. M. (2024). Top advances of the year: Cervical cancer. Cancer, 130(15), 2571-2576. https://doi.org/10.1002/cncr.35334

Vancouver

Duska LR, Podwika SE, Randall LM. Top advances of the year: Cervical cancer. Cancer. 2024;130(15):2571-2576. doi:10.1002/cncr.35334

BibTeX
@article{Duska2024,
  author = {Duska, Linda R and Podwika, Sarah E and Randall, Leslie M},
  title = {Top advances of the year: Cervical cancer},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {15},
  pages = {2571--2576},
  doi = {10.1002/cncr.35334}
}
Kostenlos starten →